HGC019
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Other names | HGCO19 |
Routes of administration | Intramuscular |
ATC code |
|
Part of a series on the |
COVID-19 pandemic |
---|
|
Timeline 2019 2020
2021
2022 |
Locations By country and territory
By conveyance
|
International response
National responses |
Medical response
Vaccines
Vaccine candidates
|
Economic impact and recession
By country
|
Impacts
|
COVID-19 portal |
|
HGC019 is a mRNA based COVID-19 vaccine candidate being developed by Gennova Biopharmaceuticals and HDT Bio Corp. with active support from NIH under The Indo-US Vaccine Action Program (VAP) and Department of Biotechnology, India.[1]
Clinical trials[]
The phase-I trials began in February 2021 after receiving permission from Drugs Controller General of India (DGCI),[2][3] to evaluate the safety and immunogenicity of the vaccine candidate in about 120 participants consisting of age group (18-70) years.[4]
The phase-II trials is planned to conduct with 500 participants from the age group (18-75) years.[4] On 24 August 2021, the Drugs Controller General of India gave a go ahead for phase II/III trials after it was found to safe, tolerable, and immunogenic in the phase I trial results.[5][6][7]
Economics[]
The company has received a funding of ₹250 crore (around US$33.5 million) from Government of India based on the clinical trials progress.[8]
References[]
- ^ "mRNA Vaccines – HGC019". Gennova Biopharmaceuticals Limited. Retrieved 13 January 2021.
- ^ "Indigenous mRNA vaccine candidate supported by DBT gets Drug Controller nod to initiate Human clinical trials" (Press release). Press Information Bureau. Retrieved 13 January 2021.
- ^ Raghavan P (15 December 2020). "Pune-based Gennova to begin human trials of its Covid vaccine 'soon'". The Indian Express.
- ^ a b "Safety and immunogenicity study of mRNA based vaccine (HGCO19) against COVID-19 in healthy adult participants". ctri.nic.in. Clinical Trials Registry India. Retrieved 5 June 2021.
- ^ "DBT-BIRAC supported Nation's first mRNA-based vaccine found to be safe gets a nod from the Drugs Controller General of India DCG(I) to move into Phase II/III trial" (Press release). Press Information Bureau. Retrieved 25 August 2021.
- ^ "India's first mRNA vaccine found to be safe, given nod for Phase II/III trial". mint. 24 August 2021.
- ^ Singh S (24 August 2021). "India approves further trials for first homegrown mRNA COVID-19 shot". Reuters.
- ^ Geeta N (26 May 2021). "Trials of India's first mRNA Covid vaccine by Gennova on track". The Financial Express.
External links[]
Scholia has a profile for HGC019 (Q106370223). |
- "India's mRNA vaccine candidate advances to human trial phase". Hindustan Times.
Artificial induction of immunity / Immunization: Vaccines, Vaccination, Infection, Inoculation (J07) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Development |
| ||||||||||
Classes |
| ||||||||||
Administration |
| ||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers |
| ||||||||||
Controversy |
| ||||||||||
Related |
| ||||||||||
|
COVID-19 pandemic in India | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||
Topics |
| ||||||||||||
Incidents |
| ||||||||||||
Locations |
| ||||||||||||
Legal framework |
| ||||||||||||
Agencies and institutes |
| ||||||||||||
Officials |
| ||||||||||||
COVID-19 portal |
COVID-19 pandemic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
This article about COVID-19 vaccines is a stub. You can help Wikipedia by . |
- v
- t
This article about vaccines or vaccination is a stub. You can help Wikipedia by . |
- v
- t
- Drugs not assigned an ATC code
- Clinical trials
- Indian COVID-19 vaccines
- RNA vaccines
- COVID-19 vaccine stubs
- Vaccine stubs
- Articles with short description
- Short description is different from Wikidata
- Use Indian English from August 2021
- All Wikipedia articles written in Indian English
- Use dmy dates from April 2021
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- Interlanguage link template forcing interwiki links
- All stub articles